Slideshow

Hot Topics in Rheumatoid Arthritis

Updates from the 2018 British Society for Rheumatology conference focus on RA treatment targets and resistance to biologics.

References1. Nikiphorou E, Norton S, Adam Young A, et al. Treating rheumatoid arthritis to target: is low disease activity good enough? Presented at: British Society for Rheumatology Annual Conference; May 1-3, 2018; Liverpool, UK.2. Kearsley-Fleet L, Watson K, Buch MH, et al. Refractory disease in rheumatoid arthritis: results from the British Society of Rheumatology Biologics Register for rheumatoid arthritis. Presented at: British Society for Rheumatology Annual Conference; May 1-3, 2018; Liverpool, UK.

Related Videos
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
Søren Andreas Just, MD, PhD: Developing AI to Mitigate Rheumatologist Shortages for Disease Assessment
© 2024 MJH Life Sciences

All rights reserved.